Novel agents and targets in managing patients with metastatic prostate cancer
WW Tan - Cancer Control, 2006 - journals.sagepub.com
WW Tan
Cancer Control, 2006•journals.sagepub.comBackground Docetaxel has recently been found to improve survival in patients with
metastatic androgen-independent prostate cancer (AIPC). Chemotherapy as a first-line
option leaves room for improvement, while second-line options are multiple and somewhat
controversial. Methods Clinically relevant articles focusing on chemotherapy drugs for
metastatic prostate cancer and their mechanism of action and efficacy were reviewed from
January 2004 through April 2006. Results Docetaxel is the standard of care for AIPC …
metastatic androgen-independent prostate cancer (AIPC). Chemotherapy as a first-line
option leaves room for improvement, while second-line options are multiple and somewhat
controversial. Methods Clinically relevant articles focusing on chemotherapy drugs for
metastatic prostate cancer and their mechanism of action and efficacy were reviewed from
January 2004 through April 2006. Results Docetaxel is the standard of care for AIPC …
Background
Docetaxel has recently been found to improve survival in patients with metastatic androgen-independent prostate cancer (AIPC). Chemotherapy as a first-line option leaves room for improvement, while second-line options are multiple and somewhat controversial.
Methods
Clinically relevant articles focusing on chemotherapy drugs for metastatic prostate cancer and their mechanism of action and efficacy were reviewed from January 2004 through April 2006.
Results
Docetaxel is the standard of care for AIPC. However, for doublets with docetaxel or second-line chemotherapy, multiple studies have shown interesting and promising results with calcitriol, thalidomide, bevacizumab, satraplatin, vaccines, ixabepilone, and atrasentan.
Conclusions
Docetaxel should be considered for first-line treatment of metastatic AIPC. Due to its progression-free survival of only 6 months, more effective drugs and drug combinations need to be developed to treat patients with AIPC. Combination treatments with docetaxel and other new agents are promising, but adequately powered phase III trials need to be conducted with survival as the principal endpoint for these promising drug combinations.
Sage Journals